




Beta Cell Preservation Work Group Monthly Meeting

April 7, 2026

Agenda

1. Welcome and updates
2. Qualitative study with Breakthrough T1D
3. Measures
4. Manuscripts
5. ISPAD submission
6. ADA presentations
7. Oral presentations for Breakthrough
8. Other business?

Beta Cell Preservation White Paper (small updates, including a landing page)



Direct link to the white paper

- <https://5087763.fs1.hubspotusercontent-na1.net/hubfs/5087763/Real%20World%20Beta%20Cell%20Preservation%20Throughout%20the%20Stages%20of%20Type%201%20Diabetes.pdf>
- Please use and share the PDF link yourself and share with members of your team
- Use the QR code/slide to share white paper with external colleagues and for presentations <https://info.t1dexchange.org/beta-cell-preservation-white-paper>
- A **Screening, Staging, and Treatment** page is also available on our member website, with additional updates coming soon

Updates: new qualitative study: March-June 2026

Exploring Clinic Practices with Type 1 Diabetes Healthcare Professionals on Recruitment for Disease-Modifying Therapy Clinical Trials

Title: Exploring Clinic Practices with Type 1 Diabetes Healthcare Professionals on Recruitment for Disease-Modifying Therapy Clinical Trials

Project Purpose:

The purpose of this project is to understand how, when, and where people newly diagnosed with Stage 3 type 1 diabetes and their families learn about disease modifying therapy (DMT) clinical trials from within clinical care settings.

This project will examine structural, behavioral, and workflow-related factors that influence whether and how healthcare professionals (HCPs) discuss DMT clinical trials with patients in endocrine and diabetes clinics.

Specifically, this project aims to:

- Learn more about when and how patients and families are informed about clinical trials in clinic settings.
- Learn about who is discussing DMT clinical trials with patients.
- Document best practices from clinics that share information on clinical trials effectively.
- Identify barriers that HCPs have when sharing information on currently recruiting clinical trials with their patients.

Breakthrough T1D intends to use this information to develop HCP resources aimed at increasing clinical trial awareness and participant enrollment.

Deliverable	Estimated Timeline (Week of)
Kickoff meeting, to occur within three weeks of executed agreement	March 23, 2026
Study Protocol <ul style="list-style-type: none"> • Interview guide development, code book formation • IRB submission for focus groups with recruitment material approval 	April 6, 2026
Focus Group Recruitment <ul style="list-style-type: none"> • Conduct 3 focus groups, including HCPs, from 6 centers 	May 25, 2026
<ul style="list-style-type: none"> • Complete analysis with development of a table with key themes (brief report) 	
Survey Development <ul style="list-style-type: none"> • Draft survey and receive IRB approval 	June 29, 2026
Deliverable	Timeline (Week of)
Survey Analysis <ul style="list-style-type: none"> • Launch survey and collect responses • Data cleaning and analysis • Prepare data tables 	Aug 17, 2026
Final Report <ul style="list-style-type: none"> • Prepare a report with major quantitative and qualitative findings with recommendations for HCPs 	Sept 28, 2026
Abstract Submission <ul style="list-style-type: none"> • Prepare an abstract for submission at a major diabetes conference 	TBD
Manuscript 1 Draft <ul style="list-style-type: none"> • Deliver a complete first draft including text, tables/figures and references 	By 12/31/2026

Screening and Monitoring Manuscripts

- The “Bringing Early Detection to Life: Real-World Operationalization of a Presymptomatic Type 1 Diabetes Screening and Monitoring Pilot Program” manuscript was submitted back to BMJ Open Diabetes Research & Care after revisions were made last week on 4/2/2026
- The "perspectives" paper, "A Real-World Beta-Cell Preservation Framework in Type 1 Diabetes: Consensus from the T1D Exchange (T1DX-QI)" will be submitted to Endocrine Practice. First draft of reformat was finished by David Broome 4/7/2026.
- Screening manuscript update: co-first authors, Lauren Culbreth and Lydia Holly. First draft will be ready in May.

Measures update

- We are currently drafting screening measures into data specification format and will present these in their final draft state at the next Data Science Committee meeting in May
- **Currently collecting:**
 - Autoantibody labs (GAD65, IA-2A, ZnT8A, IAA, ICA) based on LOINC codes, their status (completed/cancelled/ordered), value (as numeric, see below), date of that lab
- **Need confirmation on:**
 - **Screening** – is this referring to if screening occurred (Y/N)
 - **Screening result-** Positive/Negative? Single/Multiple?
 - Positive autoantibody reference ranges (value cutoffs)
 - **Therapy prescribed-** is this Y/N it was prescribed? or what kind?
 - Options for **therapy completed:**
 - 1=completed, 2=partially completed, 3=unknown, 4=therapy declined?
 - **Therapy side effects?**

Texas Smartform Updates

Method of detecting dysglycemia	Fasting BG	Random BG	HbA1c	OGTT
	CGM	Other		
Has patient received counseling for teplizumab?	yes	no	NA	other
Stage 3 T1D status	known	NA	unknown	other
Stage 3 T1D date	<input type="text"/>			
Positive antibodies	GAD65 Glutamic acid decarboxylase 65		IA-2A Insulinoma-associated antigen 2	
	IAA Insulin autoantibody		ICA Islet cell autoantibody	
	ZnT8 Zinc transporter-8 autoantibody		No positive antibodies	
	Antibodies have not been checked		Other	
Antibody testing source	Quest Diagnostics		Local lab/Institutional lab	
	LabCorp		Other commercial lab	
	TrialNet		Autoimmunity Screening for Kids (ASK)	
	Enable Biosciences (online ordering)		Antibodies have not been checked	
	Other			

Texas Smartform Updates

Patient offered

monitoring

TZIELD

research trials

other

Is the patient monitoring blood glucose levels at home?

Yes, with CGM

Yes, with blood glucose meter

No

Other

Has patient

yes

no

Teplizumab (TZIELD) Details

Date teplizumab was received (start date)



Did patient receive all 14 doses of teplizumab?

yes

no

How many doses of teplizumab did the patient receive?



Texas Smartform Updates

Hybrid infusion details

What significant side effects did the patient experience?

cytokine release syndrome	leukopenia / lymphopenia	serious infection
hypersensitivity	rash	elevated LFTs (AST >3x upper limit normal)
none	other	

Other side effect experienced

ADA Scientific Sessions, 2026

Oral Presentations

- 2026-A-3208
 - Operationalizing Early-Stage 1 Type 1 Diabetes and Monitoring
 - Lydia Holly, Friday June 5
- 2026-A-2696
 - Emerging T1D Screening and Intervention Programs,
 - Daniel DeSalvo, Monday June 8

Other sessions?

Breakthrough T1D Clinical & Research Congress

Friday, October 9, to Sunday, October 11, 2026, in Philadelphia, PA

- Laura Jacobsen, facilitator
- Daniel DeSalvo, speaker
- Carla Demeterco-Berggren, speaker

ISPAD Submission

- November 4-7th in Rio de Janeiro, Brazil
- Abstract submission deadline: April 22, 2026

Questions/Comments



T1D

Exchange